AstraZeneca completes strategic transaction with Almirall in respiratory disease
AstraZeneca today announced that it has completed the strategic transaction to transfer the rights to Almirall’s respiratory franchise to the company. As previously announced , the business combination gives AstraZeneca ownership of the rights for the development and commercialisation of Almirall’s proprietary respiratory business, including rights to revenues from Almirall’s existing partnerships, as well as its pipeline of investigational novel therapies. The franchise